Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%

Randomized phase II trial aims to compare surgery with or without adjuvant chemotherapy in treating patients who are pathologically diagnosed as stage I lung adenocarcinoma with micropapillary component no less than 20%.

Trial Details

NCT ID
NCT03351842
Phase
PHASE2
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • cis Platinum/Carboplatin, Pemetrexed Disodium
  • Undergo surgery
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Completely resected Stage I NSCLC as defined by the International Staging System
  • Pathologically diagnosed Stage I micropapillary predominant lung adenocarcinoma
  • Patients must be randomized within 4 weeks from the date of surgery
  • No prior chemotherapy or radiation for non-small cell lung cancer

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →